Get informed when a big investor buys or sells
+ Follow-152.62
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for 6973.TWO is -152.62. That is below the Healthcare sector average of -6.46. Investors often review this figure alongside U-Neuron Biomedical's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 6973.TWO currently prints -152.62 for PEG ratio, while the sector average sits near -6.46. That is roughly 2261.8% below the sector mean. Large gaps often invite a closer look at U-Neuron Biomedical's growth, margins, and balance sheet.
A PEG ratio of -152.62 for U-Neuron Biomedical is not 'good' or 'bad' on its own. Compare it with the peer average (-6.46) and with 6973.TWO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting 6973.TWO's PEG ratio (-152.62), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack U-Neuron Biomedical's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.